4-[(2-methoxy-ethyl)-methyl-amino]-piperidine-1-carboxylic acid tert-butyl ester | 885675-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[(2-methoxy-ethyl)-methyl-amino]-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-[2-methoxyethyl(methyl)amino]piperidine-1-carboxylate
• CAS: 885675-72-9
• 化学式: C₁₄H₂₈N₂O₃
• 分子量: 272.388
• InChiKey: KCQLRNNVATXXOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  42
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[(2-methoxy-ethyl)-methyl-amino]-piperidine-1-carboxylic acid tert-butyl ester 以 甲醇 、 二氯甲烷 为溶剂， 生成 (2-methoxy-ethyl)-methyl-piperidin-4-yl-amine hydrochloric acid salt
  参考文献：
  名称：

  WO2006/46031

  摘要：

  公开号：
• 作为产物：
  描述：

  N-(2-甲氧基乙基)甲基胺 、 1-Boc-哌啶 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 4-[(2-methoxy-ethyl)-methyl-amino]-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2006/46031

  摘要：

  公开号：

文献信息

• Pharmaceutical compounds
  申请人：Shutteleworth Stephen

  公开号：US20090131429A1

  公开（公告）日：2009-05-21

  Fused pyrimidines of formula (I): where A is a thiophene or furan ring and R 1 -R 3 and n are defined in the specification. These compounds have activity as inhibitors of PI 3 K and may thus be used to treat diseased and disorders arising from abnormal cell growth, function or behaviour associated with PI 3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

  式(I)的融合嘧啶化合物：其中A为噻吩或呋喃环，R1-R3和n在规范中有定义。这些化合物具有抑制PI3K的活性，因此可用于治疗与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和障碍，如癌症、免疫性疾病、心血管疾病、病毒感染、炎症、代谢/内分泌障碍和神经系统疾病。还描述了合成这些化合物的方法。
• PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Bayliss Tracy

  公开号：US20080242665A1

  公开（公告）日：2008-10-02

  Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R 3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  化学式Ia-d的化合物，其中X为S或O，mor为吗啡啶基团，R3为单环杂芳基团，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药学上可接受的盐，可用于调节脂质激酶包括PI3K的活性，并用于治疗由脂质激酶介导的癌症等疾病。本文公开了使用化合物Ia-d的方法，用于哺乳动物细胞中体外、体内诊断、预防或治疗这种疾病或相关病理条件。
• PHARMACEUTICAL COMPOUNDS
  申请人：Shuttleworth Stephen J.

  公开号：US20100280027A1

  公开（公告）日：2010-11-04

  Provided herein are methods of treating diseases or disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase, which method includes administering to a patient in need thereof a compound that is a fused pyrimidine of formula (I):

  本文提供了一种治疗因PI3激酶异常细胞生长、功能或行为引起的疾病或紊乱的方法，该方法包括向需要该治疗的患者施用以下化合物的融合嘧啶：(I)。
• Phosphoinositide 3-kinase inhibitor compounds and methods of use
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2518074A1

  公开（公告）日：2012-10-31

  Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  式Ia-d化合物（其中X为S或O，mor为吗啉基团，R3为单环杂芳基），包括立体异构体、几何异构体、同分异构体、溶解物、代谢物及其药学上可接受的盐，可用于调节脂质激酶（包括PI3K）的活性，以及治疗由脂质激酶介导的疾病（如癌症）。公开了使用式 Ia-d 化合物体外、原位和体内诊断、预防或治疗哺乳动物细胞中的此类疾病或相关病理状况的方法。
• TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3848367A1

  公开（公告）日：2021-07-14

  The present invention discloses a series of tricyclic compounds and use thereof in preparing a medicament for treating a disease related to CRBN protein. Specifically, the present invention discloses a derivative compound of formula (1) or a pharmaceutically acceptable salt thereof.

  本发明公开了一系列三环化合物及其在制备治疗 CRBN 蛋白相关疾病的药物中的用途。具体而言，本发明公开了一种式（1）的衍生物化合物或其药学上可接受的盐。